Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Private equity firms Blackstone and Bain Capital are close to finalizing a potential $3 billion deal for Mitsubishi's pharma unit, Mitsubishi Tanabe Pharma. In other news, five drugs have been flagged for unjustified price hikes in 2023 by the Institute for Clinical and Economic Review. Incyte and Iteos are cutting drug candidates from their cancer pipelines due to disappointing data, while the FDA advisory committee has called for more research on Moderna's RSV vaccine after safety issues arose. Layoffs have been announced at Intercept and Editas, and there has been a slowdown in M&A activity in the pharma industry this year. US Pharmacopeia is looking for expert volunteers to work on medicine quality challenges.